330 related articles for article (PubMed ID: 34716862)
21. Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer.
Patel PN; Yu XM; Jaskula-Sztul R; Chen H
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S497-504. PubMed ID: 24419754
[TBL] [Abstract][Full Text] [Related]
22. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
23. [Effect of IL-11 on the invasive and metastatic abilities of anaplastic thyroid carcinoma cells].
Jiang YE; Zhong ZM; Chen X; Wang W; Luo JZ; Wang SQ; Chu HY; Sun CZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Apr; 53(4):286-291. PubMed ID: 29747254
[No Abstract] [Full Text] [Related]
24. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
26. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.
Hanly EK; Rajoria S; Darzynkiewicz Z; Zhao H; Suriano R; Tuli N; George AL; Bednarczyk R; Shin EJ; Geliebter J; Tiwari RK
BMC Res Notes; 2014 Mar; 7():187. PubMed ID: 24673746
[TBL] [Abstract][Full Text] [Related]
27. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract][Full Text] [Related]
29. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Tumour Biol; 2017 Feb; 39(2):1010428317692252. PubMed ID: 28218042
[TBL] [Abstract][Full Text] [Related]
31. STAT3 signaling statuses determine the fate of resveratrol-treated anaplastic thyroid cancer cells.
Wu J; Li YT; Tian XT; Liu YS; Wu ML; Li PN; Liu J
Cancer Biomark; 2020; 27(4):461-469. PubMed ID: 31958078
[TBL] [Abstract][Full Text] [Related]
32. Juglone-ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities.
Gaikwad S; Chakraborty A; Salwe S; Patel V; Kulkarni S; Banerjee S
J Biochem Mol Toxicol; 2018 Sep; 32(9):e22176. PubMed ID: 29992683
[TBL] [Abstract][Full Text] [Related]
33. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Zhang X; Liu L; Deng X; Li D; Cai H; Ma Y; Jia C; Wu B; Fan Y; Lv Z
Oncogene; 2019 Jan; 38(5):699-715. PubMed ID: 30171257
[TBL] [Abstract][Full Text] [Related]
35. Use of vemurafenib in anaplastic thyroid carcinoma: a case report.
Marten KA; Gudena VK
Cancer Biol Ther; 2015; 16(10):1430-3. PubMed ID: 26176686
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
[TBL] [Abstract][Full Text] [Related]
37. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Di Desidero T; Antonelli A; Orlandi P; Ferrari SM; Fioravanti A; Alì G; Fontanini G; Basolo F; Francia G; Bocci G
Cancer Lett; 2017 Dec; 411():35-43. PubMed ID: 28964784
[TBL] [Abstract][Full Text] [Related]
38. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
39. Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer.
Lang M; Longerich T; Anamaterou C
Thyroid Res; 2023 Mar; 16(1):5. PubMed ID: 36855200
[TBL] [Abstract][Full Text] [Related]
40. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
